Rheumatoid arthritis is a systemic autoimmune rheumatic disorder of unknown etiology.
It is the most common form of inflammatory arthritis.
Patient usually complains of joint pain and/or swelling with morning stiffness that lasts for more than an hour.
Goals of treatment are clinical and radiological remission of disease and to reduce functional limitations and permanent joint damage.
The oral Janus Kinase (JAK) inhibitor upadacitinib appears to be useful in the treatment of rheumatoid arthritis (RA) patients with inadequate response to conventional synthetic disease-modifying antirheumatic drugs, with the 15-mg dose having the most favourable risk-benefit profile, according to data from the phase IIb/III SELECT-SUNRISE study.
The Bruton’s tyrosine kinase inhibitor fenebrutinib is safe and effective in the treatment of refractory rheumatoid arthritis, with the effect comparable to that observed with adalimumab, according to the results of a phase II study.
The oral Janus kinase inhibitor tofacitinib provides rapid and sustained pain relief across several inflammatory rheumatic musculoskeletal diseases, namely rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, according to a posthoc analysis of randomized controlled trials.
The risk of cardiovascular (CV) disease (CVD) is significantly higher among patients with rheumatoid arthritis (RA) than those with type 2 diabetes (T2D), results of the CARRÉ* study reveal. Such risk persisted even after adjusting for traditional CV risk factors, which suggests that systemic inflammation is an independent contributor to CV risk.
Rheumatoid arthritis (RA) patients who exhibit low rheumatoid factor (RF), as well as low disease activity, following treatment with certolizumab pegol (CZP) plus methotrexate (MTX) may be able to discontinue CZP without the increased risk of loss of remission, a recent study has shown.
Dr. Faith Chia Li-Ann, Dr. Paula P Tjokrosaputro, 20200224180010
Early diagnosis of RA is important such that treatment can be initiated early to prevent joint damage. Senior consultant Dr Faith Chia Li-Ann and senior resident Dr Paula P Tjokrosaputro from the Department of Rheumatology, Allergy and Immunology in Tan Tock Seng Hospital (TTSH), Singapore share their insights with Pearl Toh on the role of GPs in caring for patients with RA in the primary care setting.